Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

icant improvement in both motor and neurological functions in subacute ischemic stroke rats treated with NSI-566 cells seven days post-stroke with increasing intracerebral doses of NSI-566 into the stroke area. A separate research study, "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," led by Martin Marsala , M.D., professor and the head of the Neuroregeneration Laboratory at University of California, San Diego, demonstrated NSI-566 feasibility and safety in a chronic model of ischemic stroke in mini-pigs, a species that allowed for the use of human-scale transplantation tools and dosing, according to study authors.
  • Subsequent Events:
    In January 2013, Neuralstem received FDA approval to commence a Phase I safety trial of NSI-566 in chronic spinal cord injury (cSCI) patients. The open-label, multi-site study will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), designated American Spinal Injury Association AIS-A level of impairment,  between one and two years after injury. All patients will receive six injections in, or around, the injury site; the first four patients will receive 100,000 cells per injection, and the second four patients will receive 200,000 cells per injection. All patients will also receive physical therapy post-surgery, as well as immunosuppressive therapy, which will be for three months, as tolerated. The trial study period will end six months post-surgery for each patient, with a stated goal of trial completion within a one-year timeframe.
    In February 2013, the company granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a nonprofit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Si
    '/>"/>

  • SOURCE Neuralstem, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
    2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
    4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
    5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
    8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
    9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... Rice Lake, Wisconsin (PRWEB) July 22, 2014 ... will be in attendance at the 2014 NCSL ... Florida. Booth #423 will feature CONDEC pressure ... balance style weights, and the new, customized sets, ... years ago to promote cooperative efforts in solving ...
    (Date:7/22/2014)... 22, 2014  Neogen Corporation (NASDAQ: NEOG ... year, which ended May 31, increased 19% from the ... $28,158,000, compared to the prior year,s $27,190,000. Adjusted for ... per share in the current year were $0.76, compared ... income for the 2014 fiscal year established new all-time ...
    (Date:7/22/2014)... SHENZHEN, China , July 22, 2014 ... Tech), a subsidiary of BGI, the world,s largest ... a new human whole exome sequencing service based ... service includes in-depth bioinformatics analysis and SNP validation, ... 31, 2014. Complete Genomics, highly ...
    (Date:7/22/2014)... July 22, 2014  The Broad Institute today ... philanthropist Ted Stanley aimed at galvanizing ... treatments based on molecular understanding to hundreds of ... The Stanley commitment – the largest ever ... scientific research in general – will support research ...
    Breaking Biology Technology:Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10
    ... Company Posts Record Quarterly EPS of $0.58, 45% Above Prior Year, Based ... - Total Revenues Increase 21% to Establish Quarterly Record of $122.6 Million, ... 2008, Company Now Expects EPS of $1.72 to $1.76, Total Revenues of ... $450 to $455 Million -, ...
    ... commercial launch of first ... ... medicine,company, announced that Al Lucas has joined the Company as vice ... marketing,plan and initial launch strategy, building the sales force, and leading ...
    ... ,Monsanto Company (NYSE: MON ) and Mendel ... the development of Mendel,s BioEnergy,Seeds & Feedstocks business. ... from Monsanto,s industry-leading expertise in the testing,breeding, and ... worked together on the development of,biotechnology traits for ...
    Cached Biology Technology:Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 2Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 3Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 4Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 5Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 6Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 7Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 8Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 9Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 10Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 11Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 12Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance 13AssureRx Adds VP of Sales and Marketing 2Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration 2
    (Date:7/23/2014)... crucial for providing essential fatty acids and energy ... There has been concern that soybean-based emulsions could ... to its composition. Combination lipid emulsions based on ... been developed to address this concern. , However, ... concern may be unwarranted, according to a review ...
    (Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
    (Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
    Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
    ... appears to increase a person,s risk of developing late-onset Alzheimer,s ... will be presented as part of the late-breaking science program ... Toronto, April 10 17, 2010. The gene, abbreviated MTHFD1L, ... common variants in genes other than APOE been convincingly shown ...
    ... COLUMBUS, Ohio Scientists here are taking the trial and ... identify molecular structures that have the highest potential to serve ... designed to act on proteins that somehow malfunction in ways ... active ingredient in these medicines is typically a single molecule ...
    ... in French . , A new study, the ... techniques, to provide a more comprehensive and accurate picture of ... the April issue of neuroimaging journal Human Brain Mapping, ... and Hospital The Neuro, McGill University and the Universit ...
    Cached Biology News:New gene associated with increased risk of Alzheimer's disease 2New drug design technique could dramatically speed discovery process 2New drug design technique could dramatically speed discovery process 3Dual approach gives a more accurate picture of the autistic brain 2Dual approach gives a more accurate picture of the autistic brain 3
    100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
    Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
    Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
    Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
    Biology Products: